{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:01:12Z","timestamp":1793804472323,"version":"4.6.1"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.14364","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T11:12:09Z","timestamp":1625569929000},"page":"e2114364","source":"Crossref","is-referenced-by-count":169,"title":["Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial"],"prefix":"10.1001","volume":"4","author":[{"given":"Rema","family":"Raman","sequence":"first","affiliation":[{"name":"Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakeel T.","family":"Quiroz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Langford","sequence":"additional","affiliation":[{"name":"Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyoon","family":"Choi","sequence":"additional","affiliation":[{"name":"Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Institute for Memory Impairments and Neurological Disorders, University of California Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Baumgartner","sequence":"additional","affiliation":[{"name":"Institute for Memory Impairments and Neurological Disorders, University of California Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorene","family":"Rentz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Neurology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelum T.","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences, Rush Alzheimer\u2019s Disease Center, Rush University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Aisen","sequence":"additional","affiliation":[{"name":"Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa","family":"Sperling","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Neurology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Grill","sequence":"additional","affiliation":[{"name":"Institute for Memory Impairments and Neurological Disorders, University of California Irvine"},{"name":"Department of Psychiatry and Human Behavior, University of California Irvine"},{"name":"Department of Neurobiology and Behavior, University of California Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"issue":"3","key":"zoi210435r1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1071-9164(99)90001-5","article-title":"Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials.","volume":"5","author":"Carson","year":"1999","journal-title":"J Card Fail"},{"issue":"2","key":"zoi210435r2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1001\/archinternmed.2007.66","article-title":"Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"168","author":"Wright","year":"2008","journal-title":"Arch Intern Med"},{"issue":"6","key":"zoi210435r3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"zoi210435r4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030019","article-title":"Are racial and ethnic minorities less willing to participate in health research?","volume":"3","author":"Wendler","year":"2006","journal-title":"PLoS Med"},{"issue":"12","key":"zoi210435r5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001918","article-title":"Diversity in clinical and biomedical research: a promise yet to be fulfilled.","volume":"12","author":"Oh","year":"2015","journal-title":"PLoS Med"},{"issue":"1","key":"zoi210435r6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1212\/01.wnl.0000167545.38161.48","article-title":"Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease.","volume":"65","author":"Mehta","year":"2005","journal-title":"Neurology"},{"key":"zoi210435r7","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.0399","article-title":"Assessment of racial\/ethnic disparities in timeliness and comprehensiveness of dementia diagnosis in California.","author":"Tsoy","year":"2021","journal-title":"JAMA Neurol"},{"issue":"2","key":"zoi210435r8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3233\/JAD-200796","article-title":"Racial differences in Alzheimer\u2019s disease specialist encounters are associated with usage of molecular imaging and dementia medications: an enterprise-wide analysis using i2b2.","volume":"79","author":"Murchison","year":"2021","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"zoi210435r9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1037\/0022-006X.64.5.875","article-title":"Issues and recommendations for the recruitment and retention of older ethnic minority adults into clinical research.","volume":"64","author":"Are\u00e1n","year":"1996","journal-title":"J Consult Clin Psychol"},{"key":"zoi210435r10","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1097\/WAD.0b013e3181f12432","article-title":"Challenges and opportunities: recruitment and retention of African Americans for Alzheimer disease research: lessons learned.","volume":"24","author":"Ballard","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"zoi210435r11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3747\/co.25.3857","article-title":"Barriers to participation in clinical trials: a physician survey.","volume":"25","author":"Mahmud","year":"2018","journal-title":"Curr Oncol"},{"issue":"3","key":"zoi210435r13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/alz.v17.3","article-title":"2021 Alzheimer\u2019s disease facts and figures.","volume":"17","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"3","key":"zoi210435r14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jalz.2015.12.007","article-title":"Inequalities in dementia incidence between six racial and ethnic groups over 14 years.","volume":"12","author":"Mayeda","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"1","key":"zoi210435r15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jalz.2016.06.2360","article-title":"Systematic review of dementia prevalence and incidence in United States race\/ethnic populations.","volume":"13","author":"Mehta","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"3","key":"zoi210435r16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1017\/S104161020700511X","article-title":"Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future.","volume":"19","author":"Faison","year":"2007","journal-title":"Int Psychogeriatr"},{"issue":"4","key":"zoi210435r17","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1377\/hlthaff.2013.1353","article-title":"Alzheimer\u2019s disease in African Americans: risk factors and challenges for the future.","volume":"33","author":"Barnes","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"zoi210435r18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fnagi.2016.00123","article-title":"Underrepresentation of African-Americans in Alzheimer\u2019s trials: a call for affirmative action.","volume":"8","author":"Shin","year":"2016","journal-title":"Front Aging Neurosci"},{"issue":"228","key":"zoi210435r19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci Transl Med"},{"issue":"111","key":"zoi210435r20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002609","article-title":"Testing the right target and right drug at the right stage.","volume":"3","author":"Sperling","year":"2011","journal-title":"Sci Transl Med"},{"issue":"1","key":"zoi210435r21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.trci.2016.09.004","article-title":"African Americans are less likely to enroll in preclinical Alzheimer\u2019s disease clinical trials.","volume":"3","author":"Zhou","year":"2016","journal-title":"Alzheimers Dement (N Y)"},{"key":"zoi210435r22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.trci.2019.09.018","article-title":"Recruitment and retention of underrepresented populations in Alzheimer\u2019s disease research: a systematic review.","volume":"5","author":"Gilmore-Bykovskyi","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"zoi210435r23","article-title":"Racial and ethnic differences in older adults\u2019 willingness to be contacted about Alzheimer\u2019s disease research participation.","volume":"6","author":"Salazar","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"key":"zoi210435r24","doi-asserted-by":"publisher","first-page":"705","DOI":"10.18865\/ed.30.S2.705","article-title":"Together we make the difference: national strategy for recruitment and participation in Alzheimer\u2019s and related dementias clinical research.","volume":"30","author":"Elliott","year":"2020","journal-title":"Ethn Dis"},{"key":"zoi210435r25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.neurobiolaging.2015.11.007","article-title":"Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer\u2019s disease clinical trials.","volume":"39","author":"Grill","year":"2016","journal-title":"Neurobiol Aging"},{"issue":"1","key":"zoi210435r26","first-page":"52","article-title":"Is reluctance to share Alzheimer\u2019s disease biomarker status with a study partner a barrier to preclinical trial recruitment?","volume":"8","author":"Cox","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"zoi210435r27","first-page":"213","article-title":"Predicting amyloid burden to accelerate recruitment of secondary prevention clinical trials.","volume":"7","author":"Langford","year":"2020","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"zoi210435r28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaneurol.2020.0387","article-title":"Association of factors with elevated amyloid burden in clinically normal older individuals.","volume":"77","author":"Sperling","year":"2020","journal-title":"JAMA Neurol"},{"issue":"2","key":"zoi210435r29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/WAD.0000000000000151","article-title":"The effectiveness of small-group community-based information sessions on clinical trial recruitment for secondary prevention of Alzheimer\u2019s disease.","volume":"31","author":"Tarrant","year":"2017","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"5","key":"zoi210435r30","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1177\/1740774508096314","article-title":"Recruitment of a racially and ethnically diverse sample into a physical activity efficacy trial.","volume":"5","author":"Frierson","year":"2008","journal-title":"Clin Trials"},{"issue":"1","key":"zoi210435r31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/geront\/43.1.45","article-title":"Recruitment and retention of Latino dementia family caregivers in intervention research: issues to face, lessons to learn.","volume":"43","author":"Gallagher-Thompson","year":"2003","journal-title":"Gerontologist"},{"issue":"3","key":"zoi210435r32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1212\/WNL.0b013e31827debfe","article-title":"Effect of study partner on the conduct of Alzheimer disease clinical trials.","volume":"80","author":"Grill","year":"2013","journal-title":"Neurology"},{"key":"zoi210435r33","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.2734","article-title":"Short-term psychological outcomes of disclosing amyloid imaging results to research participants who do not have cognitive impairment.","author":"Grill","year":"2020","journal-title":"JAMA Neurol"},{"issue":"2","key":"zoi210435r34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S0197-2456(97)00118-9","article-title":"Threats to the validity of clinical trials employing enrichment strategies for sample selection.","volume":"19","author":"Leber","year":"1998","journal-title":"Control Clin Trials"},{"issue":"1","key":"zoi210435r35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13195-017-0315-1","article-title":"Race modifies the relationship between cognition and Alzheimer\u2019s disease cerebrospinal fluid biomarkers.","volume":"9","author":"Howell","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"zoi210435r36","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1001\/jamaneurol.2018.4249","article-title":"Assessment of racial disparities in biomarkers for Alzheimer disease.","volume":"76","author":"Morris","year":"2019","journal-title":"JAMA Neurol"},{"issue":"12","key":"zoi210435r37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.17363","article-title":"Racial disparity in cerebrospinal fluid amyloid and tau biomarkers and associated cutoffs for mild cognitive impairment.","volume":"2","author":"Garrett","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi210435r38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/WAD.0b013e3181c1ee01","article-title":"Recruitment of a community-based cohort for research on diversity and risk of dementia.","volume":"24","author":"Hinton","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"zoi210435r39","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/WAD.0b013e3181f12755","article-title":"Beyond diversity to inclusion: recruitment and retention of diverse groups in Alzheimer research.","volume":"24","author":"Dilworth-Anderson","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"8","key":"zoi210435r40","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/jgs.1997.45.issue-8","article-title":"Eligibility of Alzheimer\u2019s disease clinic patients for clinical trials.","volume":"45","author":"Schneider","year":"1997","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"zoi210435r41","article-title":"The Area Deprivation Index: a novel tool for harmonizable risk assessment in Alzheimer\u2019s disease research.","volume":"6","author":"Zuelsdorff","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"key":"zoi210435r12","unstructured":"US Food and Drug Administration. Guidance for industry and FDA staff: enhancing the diversity of clinical trial populations\u2014eligibility criteria, enrollment practices, and trials designs. Created November 2020. Accessed May 20, 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2781625\/raman_2021_oi_210435_1624563423.93768.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T11:12:24Z","timestamp":1625569944000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2781625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.14364","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]}}}